Testing rituximab for heart attack patients
Part of Heart & circulation clinical trials.
This study tests whether adding the drug rituximab to standard heart attack treatment can reduce damage to the heart muscle after a heart attack. Rituximab is usually used for immune system conditions, and it may help calm inflammation and protect the heart. Participants must have a certain type of heart attack and be treated quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be having a type of heart attack called ST-elevation myocardial infarction (STEMI) that affects the front or lower part of the heart with significant blockage.
- Your heart attack symptoms must have started within the last 48 hours.
- You must be scheduled to have a procedure to open the blocked artery (primary PCI) within 2 hours of diagnosis.
- You must be able to receive the study drug (rituximab) within 3 hours of that procedure.
- You must not have had a previous heart attack that left your heart pumping weakly (ejection fraction less than 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.
This study tests a drug called ziltivekimab to see if it can reduce fatty plaque buildup in heart arteries after a heart attack. It's for people who had a heart attack treated with a stent and have mild blockages in other arteries.
This trial tests whether giving a strong cholesterol-lowering treatment within 24 hours of a heart attack (during the procedure to open blocked arteries, called PCI) can reduce the risk of further heart problems. It aims to see if a rapid drop in cholesterol helps patients recover better.
This study tests whether a remote, arm-based treatment done around the time of a heart attack can improve outcomes in people with STEMI (a serious heart-attack type). Some participants receive the real treatment and some receive a sham version, while others may be followed observationally depending on how long ago symptoms started.
This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.
Hear when a new ST Elevated Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.